SCHEMBL15034867

SCHEMBL15034867

CCC(CC)c1cc2cnc(Nc3ccc(C4CNCCS4)cc3)nc2n(Cc2ncccc2-c2ccncc2)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 5/20 0.38
EGFR P00533 3/20 0.38
CDK4 P11802 4/20 0.36
CCND1 P24385 4/20 0.36
CCND2 P30279 3/20 0.36
CCND3 P30281 3/20 0.36
RIPK2 O43353 2/20 0.34
ACVR1 Q04771 2/20 0.34
NOD2 Q9HC29 2/20 0.34
JAK2 O60674 1/20 0.34
BRD4 O60885 1/20 0.34
JAK1 P23458 1/20 0.34
BRD2 P25440 1/20 0.34
JAK3 P52333 1/20 0.34
BRD3 Q15059 1/20 0.34
BRDT Q58F21 1/20 0.34
SRC P12931 1/20 0.33
CDK2 P24941 3/20 0.33
CCNA2 P20248 2/20 0.33
FGFR2 P21802 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035860 0.83 CDK4 (0.35) FGFR1EGFRCDK4CCND1CCND2
SCHEMBL15035776 0.82 FGFR1 (0.34) FGFR1EGFRCDK4CCND1CCND2
SCHEMBL15035001 0.80 CDK4 (0.36) FGFR1CDK4CCND1CCND2CCND3
SCHEMBL15035502 0.77 CDK4 (0.38) FGFR1CDK4CCND1CCND2CCND3
SCHEMBL15034963 0.76 CDK4 (0.38) FGFR1EGFRCDK4CCND1CCND2
SCHEMBL15258295 0.75 MAP4K1 (0.35) FGFR1EGFRCDK4CCND1CCND2
SCHEMBL15035403 0.74 CDK4 (0.36) FGFR1CDK4CCND1CCND2CCND3
SCHEMBL15237022 0.71 BRAF (0.37) FGFR1EGFRCDK4CCND1CCND2
SCHEMBL15036066 0.71 FGFR1 (0.45) FGFR1EGFRCDK4CCND1CCND2
SCHEMBL15034854 0.71 CDK4 (0.39) FGFR1EGFRCDK4CCND1CCND2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-05 US disclosed
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-05 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK3, PAK5 FGFR1 2874/4885EGFR 2355/4885CDK4 408/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 FGFR1 1919/4885EGFR 737/4885CDK4 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.